Myriad Genetics to Release First-Quarter 2022 Financial Results on May 5, 2022

Rhea-AI Summary

Myriad Genetics (NASDAQ: MYGN) will host its first-quarter 2022 earnings conference call on May 5, 2022, at 4:30 p.m. EDT. The earnings will be released prior to market opening on the same day. Executives, including CEO Paul J. Diaz and CFO R. Bryan Riggsbee, will provide insights into the company's performance for the period ending March 31, 2022. The call can be accessed by domestic and international callers, with an archived replay available for seven days. Myriad Genetics focuses on genetic testing and precision medicine to enhance healthcare outcomes.

Positive

• Company recognized as one of the World’s Most Innovative Companies for 2022 by Fast Company.

Negative

• None.

SALT LAKE CITY, April 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first-quarter 2022 earnings conference call on Thursday, May 5, 2022 at 4:30 p.m. EDT. The company’s quarterly earnings will be released the same day prior to the market opening.

During the call, Paul J. Diaz, president and CEO, R. Bryan Riggsbee, chief financial officer, and Nicole Lambert, chief operating officer, will provide a financial overview and business update of Myriad’s performance for the period ending March 31, 2022.

The dial-in number for domestic callers is 1-800-954-0620. International callers may dial 1-212-231-2920. All callers will be asked to reference reservation number 22018216. An archived replay of the call will be available for seven days by dialing 1-800-633-8284 and entering the reservation number above. The conference call along with a slide presentation will be available through a live webcast at www.myriad.com.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit www.myriad.com.

Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries.

Media Contact: Megan Manzari (385) 318-3718 Megan.Manzari@myriad.com

Investor Contact: Nathan Smith (801) 505-5067 Nathan.Smith@myriad.com

FAQ

When is Myriad Genetics' first-quarter 2022 earnings conference call?

The earnings conference call will be on May 5, 2022, at 4:30 p.m. EDT.

What will be discussed during the Myriad Genetics earnings call?

Executives will provide a financial overview and business update for the period ending March 31, 2022.

How can I listen to the Myriad Genetics earnings call?

The call can be accessed via a dial-in number for domestic and international callers and will also be available through a live webcast on the company's website.

What is the reservation number for the Myriad Genetics earnings call?

Callers should reference reservation number 22018216.

What is the significance of Myriad Genetics' innovation recognition?

The recognition indicates Myriad's leadership in genetic testing and precision medicine, which can positively impact its market position.